ExonHit Announces the Inclusion of Proprietary Lead Compounds into Allergan Collaboration
News Feb 24, 2010
ExonHit Therapeutics has announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan
ExonHit Therapeutics has announced the inclusion of proprietary lead compounds, which were derived from one of its internal medicinal chemistry programs, into its productive and long-running strategic collaboration with Allergan.
"We are very fortunate to have a strong and productive partnership with Allergan, which allows both companies to take advantage of opportunities to shorten development timelines and rapidly move to create new shared products and value," stated Loic Maurel M.D., President of ExonHit Therapeutics' Management Board.
ExonHit will continue to lead the medicinal chemistry effort related to this target. The compounds are active against a new enzyme target potentially useful for therapeutic development in ophthalmology and neurodegenerative indications.
Milestone and royalty terms of the existing collaboration agreement will apply to these compounds and the products derived from them.
Methane Hydrate Formation Studied Using Novel MicroreactorNews
Researchers at the NYU Tandon School of Engineering are using a novel means of studying how methane and water form methane hydrate that allows them to examine discrete steps in the process faster and more efficiently.READ MORE
University of Huddersfield Honorary Award Goes to RSC’s First Woman PresidentNews
The first woman President of the Royal Society of Chemistry, Professor Lesley Yellowlees, will collect an honorary award from University of Huddersfield, which will be presented at the University’s November Award Ceremonies.READ MORE
Drug Discovery Alliance Formed to Help Increase Drug Development Success RateNews
Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development.READ MORE